Identifying a treatment for macular oedema secondary to CRVO


A review of the various studies that have investigated the best way to treat macular oedema secondary to CRVO.

More recently, several smaller series have described improvements in both macular thickness and VA in patients treated with intravitreal triamcinolone acetonide (IVTA).6-13 The purpose of this article is to review the safety and efficacy of IVTA for the treatment of macular oedema secondary to CRVO and to discuss other, more recent, approaches to the management of this common retinal vascular condition.

Let's look at the case for triamcinolone

By one year postoperatively, 50% of eyes had received more than one injection (mean number of injections 1.6; range 1- 4). There was some overall improvement in VA within the first six months but this was not sustained at one year. Median VA change was +1 line at one and three months and no lines at six and 12 months. The VA outcomes were slightly worse when patients with extremely poor baseline VA (worse than 20/400) were removed from the analysis. At three and six months, the median VA change from baseline was no lines, and at 12 months the median VA change from baseline was -1 line.

Our one-year VA results were essentially no different to the one-year results of the Central Vein Occlusion Study; the largest study to evaluate the natural history and treatment of CRVO.1 In the macular oedema treatment group (group M) of the Central Vein Occlusion Study, the mean VA change in the untreated group (78 control eyes) was -1 letter at four months and -3 letters at 12 months.2

Related Videos
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network
Baruch Kuppermann, MD, PhD
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns."
Ash Abbey, MD, shares 36-month data from the GALE study of pegcetacoplan
© 2024 MJH Life Sciences

All rights reserved.